Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Results of Operations and Financial Condition

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Story continues below

On August 2, 2017, Sucampo Pharmaceuticals, Inc. (“the Company”) announced its consolidated financial results for the second quarter ended June 30, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 7.01 Regulation FD Disclosure.

On August 2, 2017, the Company will host a conference call with investors to discuss the Company's financial and operating results for the second quarter ended June 30, 2017. The conference call including slides will be made available to the public via conference call and webcast. The slides from the presentation are being furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.2 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

99.1Press Release issued by the Company on August 2, 2017.

99.2The corporate update presentation slides dated August 2, 2017.


Sucampo Pharmaceuticals, Inc. Exhibit
EX-99.1 2 exh_991.htm EXHIBIT 99.1 EdgarFilingEXHIBIT 99.1Sucampo Reports Second Quarter 2017 Financial Results Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse Inc. Acquisition; EPS were $0.28 on an Adjusted Diluted Basis Excluding IP R&D Charge and Other Adjustments* CPP-1X/Sulindac Phase 3 Trial for the Treatment of Familial Adenomatous Polyposis Continues After Planned Interim Futility Analysis Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. ET ROCKVILLE,…
To view the full exhibit click here

About Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009.

An ad to help with our costs